NAS:ALBO (USA) Also trade in: Germany

Albireo Pharma Inc

$ 31.41 0.31 (1%)
Volume: 15,788 Avg Vol (1m): 55,453
Market Cap $: 378.14 Mil Enterprise Value $: 227.80 Mil
P/E (TTM): 0.00 P/B: 3.35
Earnings Power Value -1569.11
Net Current Asset Value 7.73
Tangible Book 7.84
Projected FCF -20.22
Median P/S Value 3.53
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 8/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
89.52% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
ALBO: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 8.1, Med: 10000, Max: 10000
Current: 10000
8.1
10000
Equity-to-Asset 0.64
Equity-to-Asset ranked higher than
56.88% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
ALBO: 0.64
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.64, Med: 0.74, Max: 0.91
Current: 0.64
0.64
0.91
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.69
DISTRESS
GREY
SAFE
Beneish M-Score -2.67
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 14.01%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -2618.03
Operating Margin ranked lower than
57.58% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
ALBO: -2618.03
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -2457700, Med: -1228998.71, Max: -297.41
Current: -2618.03
-2457700
-297.41
Net Margin % -2900.81
Net Margin ranked lower than
58.08% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
ALBO: -2900.81
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -2441400, Med: -1220880.97, Max: -361.94
Current: -2900.81
-2441400
-361.94
ROE % -44.94
ROE ranked higher than
59.76% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
ALBO: -44.94
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -102.66, Med: -56.68, Max: -34.65
Current: -44.94
-102.66
-34.65
ROA % -31.53
ROA ranked higher than
61.62% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
ALBO: -31.53
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -83.02, Med: -47.42, Max: -28.58
Current: -31.53
-83.02
-28.58
ROC (Joel Greenblatt) % -29324.12
ROC (Joel Greenblatt) ranked lower than
87.36% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
ALBO: -29324.12
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -29324.12, Med: -1748.02, Max: -401.87
Current: -29324.12
-29324.12
-401.87
3-Year Total EBITDA Growth Rate -27.00
3-Year EBITDA Growth Rate ranked higher than
92.14% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
ALBO: 37.9
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -50.9, Med: 37.4, Max: 47.1
Current: 37.9
-50.9
47.1
3-Year EPS w/o NRI Growth Rate 34.00
3-Year EPS w/o NRI Growth Rate ranked higher than
87.16% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
ALBO: 34
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -44.7, Med: 36, Max: 46
Current: 34
-44.7
46

» ALBO's 30-Y Financials

Financials (Next Earnings Date: 2019-08-07)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ALBO

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare XKRX:052020 NAS:KERX SZSE:300705 ROCO:4162 NAS:ASMB NYSE:RCUS XKRX:208340 TSXV:EMH NAS:KALV OSTO:PROB NAS:CYCN NAS:ACHN XPAR:IPH NAS:MITO NAS:ADAP NAS:AGEN NAS:PGNX NAS:BDSI NAS:SVRA NAS:FTSV
Traded in other countries BDQM.Germany
Address 10 Post Office Square, Suite 502, South Boston, MA, USA, 02109
Albireo Pharma Inc is a development-stage pharmaceutical company. It engages in the research and development of the drug reformulation technology.

Ratios

Current vs industry vs history
PB Ratio 3.35
PB Ratio ranked higher than
68.19% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
ALBO: 3.35
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.01, Med: 2.99, Max: 5.16
Current: 3.35
2.01
5.16
PS Ratio 178.47
PS Ratio ranked lower than
67.49% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
ALBO: 178.47
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 1.86, Med: 20.09, Max: 206.59
Current: 178.47
1.86
206.59
EV-to-EBIT -4.14
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
ALBO: -4.14
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -12.8, Med: -4.9, Max: 0.2
Current: -4.14
-12.8
0.2
EV-to-EBITDA -4.14
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
ALBO: -4.14
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -12.8, Med: -4.9, Max: 0.2
Current: -4.14
-12.8
0.2
EV-to-Revenue 108.07
EV-to-Revenue ranked lower than
52.27% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
ALBO: 108.07
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -0.4, Med: 13.55, Max: 135.7
Current: 108.07
-0.4
135.7
Current Ratio 15.53
Current Ratio ranked higher than
94.69% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
ALBO: 15.53
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.82, Med: 11.86, Max: 27.25
Current: 15.53
0.82
27.25
Quick Ratio 15.53
Quick Ratio ranked higher than
94.79% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
ALBO: 15.53
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.82, Med: 11.86, Max: 27.25
Current: 15.53
0.82
27.25

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -79.50
3-Year Share Buyback Rate ranked lower than
95.33% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
ALBO: -79.5
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -126.1, Med: -45.1, Max: -5.6
Current: -79.5
-126.1
-5.6

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.01
Price-to-Tangible-Book ranked higher than
71.36% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
ALBO: 4.01
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.56, Med: 2.31, Max: 11.66
Current: 4.01
0.56
11.66
Price-to-Median-PS-Value 8.90
Price-to-Median-PS-Value ranked lower than
96.90% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
ALBO: 8.9
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.1, Med: 1.06, Max: 9.12
Current: 8.9
0.1
9.12
Earnings Yield (Joel Greenblatt) % -24.20
Earnings Yield (Greenblatt) ranked lower than
63.64% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
ALBO: -24.2
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -3385.1, Med: -19.35, Max: 1169.9
Current: -24.2
-3385.1
1169.9

More Statistics

Revenue (TTM) (Mil) $ 2.11
EPS (TTM) $ -5.12
Beta 2
Volatility % 36.16
52-Week Range $ 19.1 - 38.69
Shares Outstanding (Mil) 12.04

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N